Monthly Newsletter from the Arizona Asthma Coalition |
|
|
|
|
Mark Your Calendars for the Arizona Asthma & Allergy Conference on September 20!
Annual Arizona Asthma & Allergy Conference
Saturday, September 20, 2025
Creighton University - Health Sciences Campus Phoenix
3100 N Central Ave, Phoenix, AZ 85012
Details coming soon!
|
|
|
What doctors wish patients knew about asthma American Medical Association
Asthma can be life-threatening if you don’t get treatment. Two physicians, from Bayhealth and Rush University System for Health, share more.
|
|
|
|
|
Children exposed to higher ozone levels early in life are more likely to develop asthma
University of Washington
Asthma affects more than 6% of U.S. children, making it the most common chronic disease in kids nationwide. It’s difficult to isolate any single cause, but one of the most common contributors is air pollution: Studies have shown that breathing air with high levels of fine particulate matter, nitrogen dioxide and other environmental pollutants can increase children’s risk of developing asthma. But it’s been unclear whether long-term, early childhood exposure to ozone, the pollutant that most frequently exceeds U.S. air quality standards, contributes to the disease. |
|
|
|
|
European regulators to review GSK's asthma drug Nucala to treat COPD
Reuters
The European Medicines Agency will review GSK's (GSK.L), opens new tab request to approve its asthma drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype, the British drugmaker said on Monday. |
|
|
|
|
Breakthrough Asthma Treatment Offers Long-Lasting Relief
Sci Tech Daily
New therapeutic “cocktails” could offer long-lasting relief for treatment-resistant asthma and other inflammatory diseases of the immune system. Current asthma treatments are ineffective for some patients and do not provide long-term relief from potentially deadly asthma attacks. Scientists at La Jolla Institute for Immunology (LJI) are developing a new type of therapy. |
|
|
|
|
Cost Analysis of SMART Therapy to Improve Asthma Outcomes
American Lung Association
National asthma guidelines published in 2020 recommend that most patients with moderate-to-severe asthma would benefit from using one inhaler that includes both a long-term anti-inflammatory medicine and quick-relief medicine. This treatment is called SMART (or MART), which stands for Single Maintenance and Reliever Therapy. Studies show that using a single inhaler reduces the risk of asthma flare-ups by about 30%, compared to using one daily maintenance inhaler plus a separate, quick-relief inhaler as needed. However, only a small number of the 25 million people with asthma in the U.S. are prescribed and use SMART.
|
|
|
|
|
A treatment-resistant, severe type of asthma successfully modeled in mice
University of Michigan Medicine
A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for asthma, including biologic therapies. This is especially true for a subtype known as eosinophilic asthma—asthma that’s related to the recruitment and overactivation of white blood cells in the lungs called eosinophils. |
|
|
|
|
Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
The Lancet
Asthma and atopic dermatitis are common allergic conditions that contribute to substantial health loss, economic burden, and pain across individuals of all ages worldwide. Therefore, as a component of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we present updated estimates of the prevalence, disability-adjusted life-years (DALYs), incidence, and deaths due to asthma and atopic dermatitis and the burden attributable to modifiable risk factors, with forecasted prevalence up to 2050. |
|
|
|
|
Join the Arizona Asthma Coalition As a nonprofit partnership since 1996, AAC has worked together with concerned stakeholders including public health, environmental quality, managed care, education, individual physicians and nurses, hospitals, foundations, families and other colleagues. Become a member of the Arizona Asthma Coalition or renew your membership and help us continue this important work. Join or renew here |
|
|
|
